We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.75 | 0.99% | 76.55 | 76.27 | 77.00 | 76.49 | 75.43 | 76.47 | 9,026,349 | 01:00:00 |
From May 2019 to May 2024
By Cecilia Butini
The E.U. Medicines Agency hasn't yet reached a conclusion on a link between AstraZeneca PLC's Covid-19 shot and a rare blood clotting condition, an agency spokeswoman told the Wall Street Journal on Tuesday, adding that a review from the agency's Pharmacovigilance Risk Assessment Committee is still underway.
The European regulator responded to a comment request after Marco Cavaleri, who is the head of EMA's vaccines strategy, told Italian daily Il Messaggero that a link between AstraZeneca's shot and the disease was clear, although the agency hadn't yet finished its review.
The EMA spokeswoman said the agency would hold a press briefing on the matter as soon as its review gets finalized, which is expected to happen on Wednesday or Thursday.
AstraZeneca told The Wall Street Journal that it would decline to comment on Mr. Cavaleri's position.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 06, 2021 10:02 ET (14:02 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
